CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma
Clinical Lung Cancer · 2026-07 · 27 (6) · 31-35
DOI: 10.1016/j.cllc.2026.05.004 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Lung Cancer, 2026-07. Verfasst von Giulia Pasello und 18 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Pleural Neoplasms, Neoadjuvant Therapy, Mesothelioma. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Istituto Oncologico Veneto IRCCS, MSD.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. Electronic address: giulia.pasello@iov.veneto.it.
- Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
- Department of Cardiac, Thoracic, Vascular Science and Public Health, University of Padova, Padova, Italy.
- Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy.
- Thoracic Surgery Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
- Mesothelioma and Rare Cancers Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Förderung
- Istituto Oncologico Veneto IRCCS
- MSD
Zitieren
APA
Pasello, G., Scattolin, D., Faccioli, E., Zucali, P. A., Marulli, G., Grosso, F., Ceresoli, G. L., Tiseo, M., Bearz, A., Cecere, F. L., Calabrò, L., Callegarin, F., Del Bianco, P., De Salvo, G. L., Pezzuto, F., Calabrese, F., Guarneri, V., Dell'Amore, A., & Rea, F. (2026). CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma. Clinical Lung Cancer, 27(6), 31-35. https://doi.org/10.1016/j.cllc.2026.05.004
Vancouver
Pasello G, Scattolin D, Faccioli E, Zucali PA, Marulli G, Grosso F, et al. CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma. Clinical Lung Cancer. 2026;27(6):31-35. doi:10.1016/j.cllc.2026.05.004
BibTeX
@article{Pasello2026,
author = {Pasello, Giulia and Scattolin, Daniela and Faccioli, Eleonora and Zucali, Paolo Andrea and Marulli, Giuseppe and Grosso, Federica and Ceresoli, Giovanni Luca and Tiseo, Marcello and Bearz, Alessandra and Cecere, Fabiana Letizia and Calabrò, Luana and Callegarin, Francesco and Del Bianco, Paola and De Salvo, Gian Luca and Pezzuto, Federica and Calabrese, Fiorella and Guarneri, Valentina and Dell'Amore, Andrea and Rea, Federico},
title = {CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma},
journal = {Clinical Lung Cancer},
year = {2026},
volume = {27},
number = {6},
pages = {31--35},
doi = {10.1016/j.cllc.2026.05.004}
}
EUVIMED